Harrow Raises $50M in Senior Notes to Fuel Growth Initiatives
Event summary
- Harrow intends to offer $50M in additional 8.625% senior unsecured notes due 2030.
- Proceeds will support general corporate purposes, including new product launches and strategic investments.
- Notes are being issued under the same indenture as $250M of existing 2030 Notes issued in September 2025.
- Offering is targeted at qualified institutional buyers and non-U.S. persons under Regulation S.
The big picture
Harrow's $50M add-on offering reflects its aggressive push to expand its ophthalmic disease management portfolio. The move comes amid heightened competition in the sector, where companies are increasingly leveraging debt to fund innovation and market expansion. The strategic use of proceeds—targeting new product launches and development—suggests Harrow is positioning itself for long-term growth, though the added leverage could introduce financial risks if execution falters.
What we're watching
- Debt Management
- How Harrow will balance its increased debt load with operational cash flow.
- Growth Execution
- Whether the $50M infusion will accelerate product development and strategic initiatives.
- Market Conditions
- The impact of broader economic trends on Harrow's ability to execute its growth plans.